Articles

AML patients who underwent allogeneic stem-cell transplantation from unrelated donors while in their second complete remission with post-transplant cyclophosphamide had similar outcomes to those who underwent transplantation while in first complete remission. Read More ›

CAR T-cell immunotherapy is highly efficient because of its ability to target specific tumor antigens. Preliminary evidence suggests that CAR T-cells directed against CD117, the KIT receptor, may emerge as a therapeutic option for advanced systemic mastocytosis. Read More ›

The phase 3 AGILE study demonstrated that ivosidenib + azacitidine therapy provided significant survival benefit compared with placebo plus azacitidine in patients with newly diagnosed IDH1 mutation–positive AML who were ineligible for intensive chemotherapy. Read More ›

Cytogenetic aberrations are rarely found by cytogenetics in systemic mastocytosis but are associated with advanced disease. Whole genome sequencing detects both chromosomal aberrations and non-KIT gene mutations and can be used as an alternative to cytogenetics for assessing disease risk. Read More ›

Addition of venetoclax to FLAG-IDA yielded high minimal residual disease–negative composite complete response rates in newly diagnosed patients with AML, accompanied by a favorable safety profile. Read More ›

Avapritinib was recently approved for treatment in advanced systemic mastocytosis after demonstrating in clinicals trials the ability to improve hematologic and bone marrow responses in patients. Read More ›

Results from an ongoing first-in-human phase 1/2 study indicated that the FLT3/SYK inhibitor HM43239 yielded a favorable safety profile and encouraging antileukemic activity in patients with relapsed/refractory AML regardless of FLT3 mutation status. Read More ›

KIT D816V mutations are highly associated with most cases of systemic mastocytosis. Avapritinib demonstrates efficacy in controlling disease progression in patients with KIT D816V mutations. Read More ›

Findings from a retrospective analysis suggested that venetoclax plus hypomethylating agent plus an FLT3 inhibitor led to significant improvement in clinical outcomes, in older and unfit patients with FLT3-mutated AML. Read More ›

Advanced systemic mastocytosis often develops in patients aged >60 years but some younger patients qualify for Medicare due to preexisting disability. All patients with advanced systemic mastocytosis require more healthcare resources and have greater medical costs. Read More ›